Atacand candesartan cilexetil
Download
1 / 13

ATACAND candesartan cilexetil - PowerPoint PPT Presentation


  • 171 Views
  • Updated On :

C. ATACAND ® (candesartan cilexetil). Cardiovascular and Renal Drugs Advisory Committee Bethesda, Maryland July 18, 2002. C. ATACAND ® Introduction and Regulatory Overview. Cindy Lancaster, MS, MBA, JD Director, Regulatory Affairs AstraZeneca . Agenda for Presentation.

Related searches for ATACAND candesartan cilexetil

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'ATACAND candesartan cilexetil' - jerom


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Atacand candesartan cilexetil l.jpg

C

ATACAND®(candesartan cilexetil)

Cardiovascular and Renal DrugsAdvisory Committee

Bethesda, Maryland

July 18, 2002


Atacand introduction and regulatory overview l.jpg

C

ATACAND®Introduction and Regulatory Overview

Cindy Lancaster, MS, MBA, JD

Director, Regulatory Affairs

AstraZeneca


Agenda for presentation l.jpg
Agenda for Presentation

Regulatory Overview Cindy Lancaster, MS, MBA, JD Director, Regulatory Affairs AstraZeneca

Comparison of Vasilios Papademetriou, MD, Antihypertensive Efficacy DSc, FACCof Candesartan Cilexetil Professor of Medicineand Losartan Georgetown University

Epidemiologic and Clinical William B. Kannel, MD, FACCSignificance of Incremental Professor of Medicine andChanges in Blood Public HealthPressure Boston University School of Medicine

Summary Cindy Lancaster, MS, MBA, JD Director, Regulatory Affairs AstraZeneca


Consultant and sponsor representatives l.jpg
Consultant and Sponsor Representatives

Consultant

  • Donald Vidt, MD, FACC

    • Principal Investigator for Study 230

    • Consultant, Department of Hypertension and Nephrology, The Cleveland Clinic Foundation

    • Professor of Medicine, Ohio State University

      AstraZeneca

  • Eric Michelson, MD, FACC

    • Senior Director, Clinical Research

  • Conrad Tou, PhD

    • Associate Director, Biostatistics

  • Jennifer Sugg, MS

    • Senior Statistical Scientist

  • Glenn Carlson, MD

    • Senior Director, Medical


Introduction l.jpg

ATACAND® (candesartan cilexetil)

Selective AT1 subtype angiotensin II receptor antagonist (ARB)

June 1998—Approved for the treatment of hypertension

Can be used alone or in combination with other antihypertensive agents

Usual recommended starting dose: 16 mg QD

Introduction


Regulatory history agency interactions 1 l.jpg
Regulatory HistoryAgency Interactions (1)

Original NDA

  • Included 1 positive comparative study versus losartan, SH-AHM-0001

    • Randomized, double-blind, multicenter, placebo-controlled, parallel-group, 8-wk duration

    • Patients (N = 337) with a mean diastolic blood pressure of 95 to 114 mm Hg

    • Compared candesartan cilexetil 8 and 16 mg QD,losartan 50 mg QD, and placebo

    • The proposed labeling did not include comparator text versus losartan


Regulatory history agency interactions 2 l.jpg
Regulatory HistoryAgency Interactions (2)

Study 175—positive results versus losartan

available in 1998

  • Randomized, double-blind, multicenter, titration-to-effect, parallel-group, 8-wk duration

  • Patients (N = 332) with a mean diastolic blood pressure of 95 to 114 mm Hg

  • Initiated treatment with candesartan cilexetil 16 mg QD or losartan 50 mg QD

  • After 4 wk, patients with a mean sitting DBP ≥ 90 mm Hg were titrated to candesartan cilexetil 32 mg QD or losartan 100 mg QD


Regulatory history agency interactions 3 l.jpg
Regulatory HistoryAgency Interactions (3)

  • August 1998 meeting with the Agency

  • Discussed use of SH-AHM-0001 and Study 175 to support a comparator claim versus losartan for the treatment of hypertension

    • SH-AHM-0001

      • A starting dose comparison does not provide a meaningful comparison because the starting dose is an arbitrary point and does not represent how the drugs perform over their dose ranges

    • Study 175

      • It was not a forced-titration design. Only poor responders would be titrated to the highest dose of the drugs in a titration-to-effect study


Regulatory history agency interactions 4 l.jpg
Regulatory HistoryAgency Interactions (4)

Agency requirements to support comparator claim:

  • Establish bioequivalence of losartan and overencapsulated tablets used in blinding of comparator product

  • Study candesartan cilexetil and losartan at the maximum approved doses for the treatment of hypertension

  • Statistically significant results replicated in adequate and well-controlled trials

  • If once-daily dosing is studied, then the limitations should be clearly stated in promotional claims

  • Acceptable study designs: parallel dose-response or forced-titration


Description of comparative trials in labeling l.jpg
Description of Comparative Trials in Labeling

  • Results of a specific dosing regimen of once-daily administration at the maximum approved dose from 2 clinical trials with hypertensive patients

  • Once-daily administration is an appropriate dosing regimen for candesartan cilexetil and losartan because:

    • Both drugs are regularly prescribed for use once daily

    • Once-daily administration is the dosing regimen primarily used in on-going and completed studies

  • Statistically greater blood pressure reduction was demonstrated with candesartan cilexetil compared with losartan at the maximum approved dose when administered once daily

  • The proposed labeling is specific to effects on blood pressure reduction


Labeling l.jpg
Labeling

PROPOSED ADDITION TO CLINICAL PHARMACOLOGY, Clinical Trials subsection (for insertion after the first paragraph in this section):

“ Two identically designed, concurrently conducted, 8-week, multicenter, double-blind, randomized, forced-titration studies were performed to compare the antihypertensive efficacy of candesartan cilexetil and losartan at their once-daily maximum doses. Candesartan cilexetil initiated at 16 mg once daily and forced- titrated at 2 weeks to 32 mg once daily was statistically significantly more effective than losartan 50 mg once daily forced-titrated at 2 weeks to 100 mg once daily in reducing systolic and diastolic blood pressure at 8 weeks. In these studies, both agents were well tolerated.”

Currently approved labeling—INDICATIONS AND USAGE:

“ ATACAND is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.”


Regulatory precedent l.jpg
Regulatory Precedent

Comparator Claim for ZESTRIL®/Prinivil® (lisinopril):

CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Hypertension  

“. . . In controlled clinical studies, ZESTRIL 20-80 mg has been compared in patients with mild to moderate hypertension to hydrochlorothiazide 12.5-50 mg and with atenolol 50-200 mg; and in patients with moderate to severe hypertension to metoprolol 100-200 mg. It was superior to hydrochlorothiazide in effects on systolic and diastolic pressure in a population that was ¾ Caucasian. ZESTRIL was approximately equivalent to atenolol and metoprolol in effects on diastolic blood pressure, and had somewhat greater effects on systolic blood pressure.”


Labeling13 l.jpg
Labeling

Proposed labeling is consistent with:

  • The general requirements of the content and format of labeling for human prescription drugs

  • Guidance during the design of the CLAIM program from the Division on how these studies should be described in labeling

  • Placement of comparator information in labeling of other antihypertensive products:

    • ZESTRIL®, COZAAR®, ACCUPRIL®, ALTACE®, DIOVAN®, TEVETEN®

  • AstraZeneca will continue to work with the Division to finalize labeling


ad